Drug Trial Radar · NCT00665925
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Sep 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
457
Actual
Start
May 2008
Primary completion
Jun 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- Rigel PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 24, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) inhibitor, R935788 (R788), at a dose of 100 mg, orally, twice-a-day, and/or a dose of of 150 mg, orally, once-a-day is effective in the treatment of Rheumatoid Arthrits in patients who have had an inadequate clinical response to methotrexate.
Conditions
- Rheumatoid Arthritis
Interventions
Fostamatinib disodium (R935788)Drug
100 mg tablet, orally, twice-a-day
Fostamatinib disodium (R935788)Drug
150 mg tablet, orally, once a day
PlaceboDrug
Placebo, orally, either once a day, or twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- American College of Rheumatology 20 (ACR20) Response at 6 MonthsTime frame: 6 months
Locations
65 sites in 6 countries. Site status is shown where the registry gives one.
Divison of Rheumatology Allergy and Immunology
La Jolla, California
Desert Medical Advances
Palm Desert, California
Arthritis & Osteoporosis Center, PC
Hamden, Connecticut
Cynthia Morgan
Washington D.C., District of Columbia
Florida Medical Research Institute
Gainsville, Florida
Paddock Park Clinical Research
Ocala, Florida
Jeffrey Poiley, MD
Orlando, Florida
Lovelace Scientific Resources
Sarasota, Florida
Rheumatology Associates, SC
Chicago, Illinois
Memorial Medical Group Clinical Research Inst
South Bend, Indiana
Center for Arthritis & Osteoporosis
Elizabethtown, Kentucky
The Osteoporosis & Clinical Trials Center
Hagerstown, Maryland
Fiechtner Research, Inc.
Lansing, Michigan
Westroads Medical Group
Omaha, Nebraska
North Carolina Arthritis & Allergy Care Center
Raleigh, North Carolina
Wake Forest University
Winston-Salem, North Carolina
Health Research of Oklahoma
Oklahoma City, Oklahoma
Rheumatology Associates
Erie, Pennsylvania
Clinical Research Center of Reading, LLP
West Reading, Pennsylvania
Rheumatic Disease Associates
Willow Grove, Pennsylvania
Rheumatology Associates
Charleston, South Carolina
Austin Rheumatology & Research
Austin, Texas
Arthritis Center of South Texas
San Antonio, Texas
Arthritis Northwest, PLLC
Spokane, Washington
MHAT Ruse
Rousse, Bulgaria
DCC "Sv. Anna" Sofia
Sofia, Bulgaria
MNTranspH "Tsar Boris Treti"
Sofia, Gsof, Bulgaria
MHAT "Kaspela"
Plovdiv, PLO, Bulgaria
Unidad Medica Torre Plaza
Medellín, Antioquia, Colombia
Centro de Reumatologia y Ortopedia
Barranquilla, Atlántico, Colombia
Reumatologos del Caribe
Barranquilla, Atlántico, Colombia
CIREEM
Bogota, Cundinamarca, Colombia
Fundación Instituto de Reumatología
Bogota, Cundinamarca, Colombia
Riesgo de Fractura S.A
Bogota, Cundinamarca, Colombia
Private Office
Bogotá, Cundinamarca, Colombia
Centro Medico Carlos Ardila Lulle
Bucaramanga, Santander Department, Colombia
SERVIMED
Bucaramanga, Santander Department, Colombia
Christus Muguerza del Parque
Chihuahua City, Chihuahua, Mexico
Arké Estudios Clínicos S.A de C.V
México, D.f., Mexico
Clínica para el Diagnostico y Tratamiento de
México, D.f., Mexico
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.